Insider Selling: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) CAO Sells 6,625 Shares of Stock

Key Points

• CAO Michael Megna sold 6,625 shares on April 9 at an average price of $46.69 (totaling $309,321.25), cutting his stake by 19.46% to 27,418 shares; the sale was executed under a pre-arranged Rule 10b5-1 plan and disclosed in an SEC Form 4.
• Kiniksa traded around $47.30 (12‑month range $19.41–$50.03) with a $3.62B market cap; the company reported Q earnings of $0.17 EPS (missed estimates) while revenue rose 65% to $202.13M, and analysts hold a consensus "Moderate Buy" with a $55.29 target.

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) CAO Michael Megna sold 6,625 shares of the firm's stock in a transaction on Thursday, April 9th. The stock was sold at an average price of $46.69, for a total transaction of $309,321.25. Following the transaction, the chief accounting officer directly owned 27,418 shares in the company, valued at $1,280,146.42. The trade was a 19.46% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kiniksa Pharmaceuticals International Stock Performance

Kiniksa Pharmaceuticals International stock traded up $0.22 during midday trading on Monday, hitting $47.30. 349,649 shares of the company's stock were exchanged, compared to its average volume of 641,653. Kiniksa Pharmaceuticals International, plc has a 12-month low of $19.41 and a 12-month high of $50.03. The stock has a market cap of $3.62 billion, a price-to-earnings ratio of 63.92 and a beta of 0.06. The firm's 50 day simple moving average is $45.95 and its 200 day simple moving average is $42.36.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last issued its quarterly earnings data on Tuesday, February 24th. The company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.12). The business had revenue of $202.13 million for the quarter, compared to analysts' expectations of $200.86 million. Kiniksa Pharmaceuticals International had a return on equity of 11.48% and a net margin of 8.71%.The company's revenue for the quarter was up 65.0% on a year-over-year basis. During the same period in the previous year, the business posted ($0.12) earnings per share. On average, equities research analysts forecast that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

KNSA has been the topic of several analyst reports. Wall Street Zen downgraded shares of Kiniksa Pharmaceuticals International from a "buy" rating to a "hold" rating in a report on Saturday, March 14th. Wedbush raised their price objective on shares of Kiniksa Pharmaceuticals International from $50.00 to $53.00 and gave the company an "outperform" rating in a research note on Wednesday, February 25th. Canaccord Genuity Group began coverage on shares of Kiniksa Pharmaceuticals International in a research note on Thursday, February 19th. They issued a "buy" rating and a $62.00 price objective for the company. Wells Fargo & Company raised their price objective on shares of Kiniksa Pharmaceuticals International from $50.00 to $53.00 and gave the company an "overweight" rating in a research note on Wednesday, February 25th. Finally, Zacks Research upgraded shares of Kiniksa Pharmaceuticals International from a "strong sell" rating to a "hold" rating in a research note on Wednesday, February 25th. Seven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $55.29.

Institutional Trading of Kiniksa Pharmaceuticals International

Hedge funds and other institutional investors have recently made changes to their positions in the stock. GSA Capital Partners LLP raised its position in Kiniksa Pharmaceuticals International by 281.9% during the third quarter. GSA Capital Partners LLP now owns 77,984 shares of the company's stock worth $3,028,000 after acquiring an additional 57,566 shares during the last quarter. Fisher Asset Management LLC raised its position in Kiniksa Pharmaceuticals International by 176.1% during the third quarter. Fisher Asset Management LLC now owns 282,288 shares of the company's stock worth $10,961,000 after acquiring an additional 180,029 shares during the last quarter. Aberdeen Group plc acquired a new position in Kiniksa Pharmaceuticals International during the third quarter worth about $6,163,000. Essex Investment Management Co. LLC raised its position in Kiniksa Pharmaceuticals International by 44.3% during the third quarter. Essex Investment Management Co. LLC now owns 247,301 shares of the company's stock worth $9,603,000 after acquiring an additional 75,864 shares during the last quarter. Finally, Campbell & CO Investment Adviser LLC acquired a new position in Kiniksa Pharmaceuticals International during the third quarter worth about $1,480,000. Institutional investors and hedge funds own 53.95% of the company's stock.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company's core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company's lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still's disease and Schnitzler syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.